Abstract
Lung cancer is a good candidate for screening. The NLST trial demonstrated that annual low-dose CT-scan in a high risk population of smokers reduced specific mortality by 20% and overall mortality by 6.7%.Current position of lung cancer screening in France and worldwide is presented in this review.In France, the topic is dominated by french heath autorithies skepticism. Worldwide there are deep differences: US and Canada have iplemented lung cancer screening in routine while Europe still waiting for NELSON results and pooled analysis of european trials.In practice, interval between two low-dose CT-scan ay be delayed at 2 years (but no more), in particular among individuals who have a negative CT-scan. Biomarkers and risk-prediction scores are clearly very interesting perpectives but need prospective validation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
